دورية أكاديمية
أعرض في EDS

Two-drug regimens for HIV treatment.

التفاصيل البيبلوغرافية
العنوان: Two-drug regimens for HIV treatment.
المؤلفون: Gibas KM; Division of Infectious Diseases, Vanderbilt University Medical Center, Vanderbilt University, Nashville, TN, USA., Kelly SG; Division of Infectious Diseases, Vanderbilt University Medical Center, Vanderbilt University, Nashville, TN, USA., Arribas JR; Infectious Diseases Unit, La Paz University Hospital, Hospital La Paz Institute for Health Research, Madrid, Spain; School of Medicine, Universidad Autónoma de Madrid, Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Infecciosas, Madrid, Spain., Cahn P; Fundación Huésped, Buenos Aires, Argentina., Orkin C; Department of Immunobiology, Queen Mary University of London, London, UK., Daar ES; The Lundquist Institute, Harbor University of California, Los Angeles, Torrence, CA, USA., Sax PE; Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA; Harvard Medical School, Harvard University, Boston, MA, USA., Taiwo BO; Division of Infectious Diseases, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. Electronic address: b-taiwo@northwestern.edu.
المصدر: The lancet. HIV [Lancet HIV] 2022 Dec; Vol. 9 (12), pp. e868-e883. Date of Electronic Publication: 2022 Oct 26.
نوع المنشور: Journal Article; Review; Research Support, U.S. Gov't, P.H.S.
اللغة: English
بيانات الدورية: Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101645355 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2352-3018 (Electronic) Linking ISSN: 23523018 NLM ISO Abbreviation: Lancet HIV Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [Amsterdam] : Elsevier B.V., [2014]-
مواضيع طبية MeSH: Anti-HIV Agents*/adverse effects , HIV Infections*/drug therapy , Hepatitis B, Chronic*/drug therapy , HIV-1*, Humans ; Tenofovir/adverse effects ; Anti-Retroviral Agents/therapeutic use ; Drug Therapy, Combination
مستخلص: Combination therapy with three antiretroviral agents has been integral to successful HIV-1 treatment since 1996. Although the efficacy, adverse effects, and toxicities of contemporary three-drug regimens have improved, even the newest therapies have potential adverse effects. The use of two-drug regimens is one way to reduce lifetime exposure to antiretroviral drugs while maintaining the benefits of viral suppression. Multiple large, randomised trials have shown the virological non-inferiority of certain two-drug regimens versus three-drug comparators, including adverse effect differences that reflect known profiles of the antiretroviral drugs in the respective regimens. Two-drug combinations are now recommended in treatment guidelines and include the first long-acting antiretroviral regimen for the treatment of HIV-1. Recommended two-drug regimens differ in their risks for, and factors associated with, virological failure and emergent resistance. The tolerability, safety, metabolic profiles, and drug interactions of two-drug regimens also vary by the constituent drugs. No current two-drug regimen is recommended for people with chronic hepatitis B virus as none include tenofovir. Two-drug regimens have increased options for individualised care.
Competing Interests: Declaration of interests SGK has served on advisory boards for Gilead, ViiV, and Theratechnologies. JRA has received advisory fees, speaker fees, and grant support from ViiV, Janssen, Gilead, Merck, Aelix, and Thera. PC has worked on advisory boards at ViiV and Merck and received research and speaker funds from ViiV, CanSino, and Janssen and has received honoraria as a data safety and monitoring board member for Moderna. CO has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Gilead, ViiV, Janssen, GlaxoSmithKline, AstraZeneca, and Merck. ESD has received research support from and is a consultant for Gilead, Merck, GlaxoSmithKline, and ViiV. PES receives research support from Gilead, GlaxoSmithKline, and ViiV. He serves as a scientific advisory board member and consultant for Gilead, GlaxoSmithKline, ViiV, Merck, and Janssen; and has editorial positions with UpToDate, Medscape, New England Journal of Medicine Journal Watch, and Open Forum Infectious Diseases. BOT has served as a consultant and received honoraria from GlaxoSmithKline, ViiV, Gilead, Merck, and Johnson & Johnson. KMG received a training grant from the Agency For Health Care Research and Quality (T32HS026122).
(Copyright © 2022 Elsevier Ltd. All rights reserved.)
التعليقات: Comment in: Lancet HIV. 2023 Mar;10(3):e150. (PMID: 36773625)
Comment in: Lancet HIV. 2023 Mar;10(3):e150-e151. (PMID: 36773626)
References: Lancet HIV. 2021 Nov;8(11):e668-e678. (PMID: 34656207)
Lancet HIV. 2021 Nov;8(11):e679-e689. (PMID: 34648734)
HIV Med. 2019 Apr;20 Suppl 4:2-12. (PMID: 30821898)
J Antimicrob Chemother. 2017 Jan;72(1):246-253. (PMID: 27629070)
AIDS. 2020 Nov 1;34(13):1899-1906. (PMID: 32701580)
J Antimicrob Chemother. 2017 Apr 1;72(4):1163-1171. (PMID: 28093483)
AIDS. 2022 Jan 1;36(1):39-48. (PMID: 34534138)
AIDS. 2022 Mar 1;36(3):459-471. (PMID: 34750289)
AIDS. 2021 Jun 1;35(7):1103-1112. (PMID: 33534204)
J Acquir Immune Defic Syndr. 2020 Nov 1;85(3):325-330. (PMID: 32675772)
PLoS One. 2019 Sep 6;14(9):e0221653. (PMID: 31490959)
J Antimicrob Chemother. 2013 Jun;68(6):1364-72. (PMID: 23372058)
J Antimicrob Chemother. 2020 Jun 1;75(6):1611-1617. (PMID: 32091102)
Clinicoecon Outcomes Res. 2017 Mar 01;9:173-179. (PMID: 28280375)
N Engl J Med. 2020 Mar 19;382(12):1124-1135. (PMID: 32130806)
Open Forum Infect Dis. 2021 Aug 25;8(9):ofab439. (PMID: 34557563)
Clin Infect Dis. 2020 Nov 5;71(8):1920-1929. (PMID: 31905383)
Lancet HIV. 2019 Sep;6(9):e576-e587. (PMID: 31307948)
N Engl J Med. 2020 Mar 19;382(12):1112-1123. (PMID: 32130809)
Lancet. 2017 Sep 23;390(10101):1499-1510. (PMID: 28750935)
AIDS. 2016 May 15;30(8):1229-38. (PMID: 26854810)
Lancet HIV. 2021 Aug;8(8):e463-e473. (PMID: 34358497)
J Int AIDS Soc. 2014 Nov 02;17(4 Suppl 3):19818. (PMID: 25397562)
Lancet. 2019 Jan 12;393(10167):143-155. (PMID: 30420123)
J Int AIDS Soc. 2021 Apr;24(4):e25702. (PMID: 33838004)
J Acquir Immune Defic Syndr. 2018 Dec 15;79(5):e112-e114. (PMID: 30383591)
JAMA. 2020 Oct 27;324(16):1651-1669. (PMID: 33052386)
Open Forum Infect Dis. 2022 Feb 10;9(4):ofac068. (PMID: 35265729)
Clin Infect Dis. 2021 Oct 20;73(8):1440-1451. (PMID: 33987636)
J Antimicrob Chemother. 2019 Sep 1;74(9):2742-2751. (PMID: 31269208)
Lancet Infect Dis. 2014 Jul;14(7):572-80. (PMID: 24783988)
Lancet Infect Dis. 2015 Jul;15(7):775-84. (PMID: 26062881)
J Antimicrob Chemother. 2020 May 1;75(5):1332-1337. (PMID: 32129855)
J Antimicrob Chemother. 2021 Feb 11;76(3):738-742. (PMID: 33200210)
Curr Opin HIV AIDS. 2016 Jul;11(4):362-70. (PMID: 27259045)
Clinicoecon Outcomes Res. 2017 Sep 27;9:569-571. (PMID: 29026324)
PLoS One. 2014 Aug 29;9(8):e106221. (PMID: 25170938)
HIV Med. 2021 Jul;22(6):519-525. (PMID: 33480094)
J Antimicrob Chemother. 2019 Aug 1;74(8):2365-2369. (PMID: 31039247)
Clin Infect Dis. 2016 Mar 15;62(6):784-91. (PMID: 26658053)
AIDS. 2021 Jul 15;35(9):1333-1342. (PMID: 33730748)
Clin Infect Dis. 2020 Sep 12;71(6):1379-1389. (PMID: 31606734)
Value Health Reg Issues. 2021 May;24:216-223. (PMID: 33857719)
AIDS. 2018 Jan 2;32(1):17-23. (PMID: 29112073)
Lancet HIV. 2020 Mar;7(3):e158-e159. (PMID: 32142711)
J Infect Dis. 2021 Jun 4;223(11):1928-1933. (PMID: 33049035)
AIDS. 2011 Nov 13;25(17):2113-22. (PMID: 21857490)
Lancet Infect Dis. 2015 Oct;15(10):1145-1155. (PMID: 26201299)
Clin Infect Dis. 2016 Jul 1;63(1):122-32. (PMID: 27048747)
Clin Infect Dis. 2017 Nov 29;65(12):2112-2118. (PMID: 29020293)
Lancet. 2021 Dec 19;396(10267):1994-2005. (PMID: 33308425)
Lancet HIV. 2021 Apr;8(4):e185-e196. (PMID: 33794181)
Clin Infect Dis. 2018 May 17;66(11):1689-1697. (PMID: 29253097)
Lancet. 2018 Mar 3;391(10123):839-849. (PMID: 29310899)
AIDS. 2021 Oct 1;35(12):1957-1965. (PMID: 34115650)
J Neurovirol. 2018 Aug;24(4):391-397. (PMID: 29542028)
Lancet Infect Dis. 2015 Jul;15(7):785-92. (PMID: 26062880)
AIDS. 2021 Dec 15;35(Suppl 2):S189-S195. (PMID: 34848586)
J Antimicrob Chemother. 2009 Jul;64(1):126-34. (PMID: 19403652)
J Acquir Immune Defic Syndr. 2020 May 1;84(1):60-65. (PMID: 31977595)
AIDS. 2014 Apr 24;28(7):943-7. (PMID: 24401641)
J Manag Care Spec Pharm. 2021 Jul;27(7):891-903. (PMID: 34185564)
Curr Opin HIV AIDS. 2021 May 1;16(3):148-151. (PMID: 33797433)
Lancet HIV. 2015 Nov;2(11):e464-73. (PMID: 26520926)
Open Forum Infect Dis. 2020 Aug 13;7(9):ofaa356. (PMID: 32965277)
Int J Antimicrob Agents. 2018 Nov;52(5):541-553. (PMID: 30040992)
Lancet. 2014 Nov 29;384(9958):1942-51. (PMID: 25103176)
AIDS. 2011 Jan 14;25(2):185-95. (PMID: 21150555)
J Antimicrob Chemother. 2014 Jun;69(6):1648-52. (PMID: 24535278)
Medicine (Baltimore). 2019 Aug;98(32):e16813. (PMID: 31393412)
HIV Clin Trials. 2012 May-Jun;13(3):119-30. (PMID: 22592092)
Clin Drug Investig. 2015 Mar;35(3):211-9. (PMID: 25637061)
J Antimicrob Chemother. 2017 Jul 1;72(7):2055-2059. (PMID: 28333353)
J Antimicrob Chemother. 2018 Sep 1;73(9):2444-2451. (PMID: 29897573)
J Antimicrob Chemother. 2018 Jul 1;73(7):1949-1954. (PMID: 29788156)
Clin Infect Dis. 2022 Sep 29;75(6):975-986. (PMID: 35079789)
J Acquir Immune Defic Syndr. 2016 Apr 15;71(5):538-43. (PMID: 26605505)
Immunity. 2013 Oct 17;39(4):633-45. (PMID: 24138880)
Top Antivir Med. 2014 Jun-Jul;22(3):651-4. (PMID: 25101530)
J Am Geriatr Soc. 2012 May;60(5):974-9. (PMID: 22568508)
معلومات مُعتمدة: L30 AI172003 United States AI NIAID NIH HHS; T32 HS026122 United States HS AHRQ HHS
المشرفين على المادة: 0 (Anti-HIV Agents)
99YXE507IL (Tenofovir)
0 (Anti-Retroviral Agents)
تواريخ الأحداث: Date Created: 20221029 Date Completed: 20221206 Latest Revision: 20230413
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC10015554
DOI: 10.1016/S2352-3018(22)00249-1
PMID: 36309038
قاعدة البيانات: MEDLINE
الوصف
تدمد:2352-3018
DOI:10.1016/S2352-3018(22)00249-1